Eliot Forster, F-star CEO
AstraZeneca takes a chance on the STING pathway with F-star
After a slew of Big Pharma companies and biotechs walked away from the STING pathway in the last few years, AstraZeneca is approaching the field with a new bet on the drug class’ next generation.
The British drugmaker is teaming up with F-star Therapeutics on a slate of preclinical STING inhibitor compounds, the companies announced Thursday morning. It’s a modest sum as these things go, with $12 million upfront and over $300 million in milestones, plus single-digit royalties.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters